Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:CCCX
NasdaqGM:CCCXCapital Markets

Churchill Capital Corp X (CCCX): Evaluating Valuation as Bullish Options Activity Spikes and Trader Optimism Grows

Bullish momentum is building around Churchill Capital Corp X (CCCX) as options traders pile into call contracts. Volumes have doubled the norm and implied volatility is spiking. The extremely low Put/Call Ratio suggests that optimism is widespread. See our latest analysis for Churchill Capital Corp X. After a quiet start to the year, Churchill Capital Corp X’s share price has climbed significantly in recent weeks, notching a 51.8% gain over the past month and doubling since the beginning of...
SEHK:1651
SEHK:1651Machinery

A Fresh Look at Precision Tsugami (China) (SEHK:1651) Valuation Following Profit Surge on Manufacturing Rebound

Precision Tsugami (China) (SEHK:1651) just released an earnings update, reporting a 48% jump in profit for the past six months. This surge was driven by China’s manufacturing rebound and increased demand from sectors such as new energy vehicles and AI. See our latest analysis for Precision Tsugami (China). Precision Tsugami (China)’s surge in profitability has caught the market’s attention. Its 1-day share price return was 7.24%, pushing the stock to $37.64. The stock has notched an...
TSE:3092
TSE:3092Specialty Retail

Is ZOZO Fairly Priced After a 16% Drop in 2025?

If you are considering what to do with your ZOZO shares right now, you are not alone. Investors are taking a close look at this Japanese e-commerce leader after a stretch of uneven performance. There is no denying the excitement around ZOZO’s longer-term record, with the stock up 70.1% over the last five years and climbing 40.4% over three. However, more recent returns have been less inspiring. Over the past year, ZOZO’s share price has fallen 16.2%, a trend that continued into this year with...
NYSE:WKC
NYSE:WKCOil and Gas

World Kinect (WKC) Forecasts 126% Annual Earnings Growth, Profitability Outlook Challenges Bearish Narrative

World Kinect (NYSE:WKC) remains unprofitable, with losses deepening at an average rate of 45.7% per year over the last five years and no improvement in its net profit margin this year. Revenue is forecast to edge down slightly by 0.01% per year in the near term, but the major storyline is an expected earnings turnaround. Analysts see profits growing by 125.91% per year, with the company potentially returning to profitability within three years, an outlook that stands out in the sector. See...
OM:SIVE
OM:SIVESemiconductor

Sivers Semiconductors (OM:SIVE) Revenue Set to Grow 21% Annually, Losses Narrowing—Earnings Preview

Sivers Semiconductors (OM:SIVE) remains unprofitable, but its revenue is projected to grow at an impressive 21% per year. This pace is well ahead of the Swedish market's 3.8% rate. Over the past five years, the company's losses have narrowed at a rate of 8.1% per year, though forecasts suggest it will remain in the red for at least the next three years. Investors are likely to focus on ongoing revenue growth and shrinking losses as they weigh the prospects for eventual profitability in light...
NasdaqGS:CSGS
NasdaqGS:CSGSProfessional Services

How Investors May Respond To CSG Systems International's (CSGS) New Formula 1 Partnership for Brand Expansion

MoneyGram Haas F1 Team recently announced a new partnership with CSG Systems International, debuting their collaboration at the 2025 Formula 1 United States Grand Prix in Austin, Texas, to emphasize their shared commitment to innovation and performance. This partnership leverages the global exposure and fast-paced environment of Formula 1 racing to highlight CSG's expertise in empowering brands to engage customers and manage complexity. We'll now examine how CSG's new Formula 1 alliance...
NasdaqGM:ARCT
NasdaqGM:ARCTBiotechs

Arcturus Therapeutics (ARCT): Evaluating Valuation After Cystic Fibrosis Trial Setback and Heightened Regulatory Scrutiny

Arcturus Therapeutics Holdings (ARCT) drew intense investor attention after it released interim results from a Phase 2 trial for its cystic fibrosis treatment, ARCT-032. The report showed no substantial lung function improvement, which triggered sharp share declines and analyst downgrades. See our latest analysis for Arcturus Therapeutics Holdings. It has been a turbulent year for Arcturus Therapeutics. Shares have dropped sharply after underwhelming trial news and legal scrutiny, leading to...
NasdaqCM:COYA
NasdaqCM:COYABiotechs

Coya Therapeutics (COYA): Evaluating Valuation After Equity Raise and Milestone Progress in ALS Program

Coya Therapeutics has completed a $20 million follow-on equity offering. The company aims to strengthen its cash position and accelerate progress in the Phase 2 trial of COYA 302, its experimental ALS therapy. Investors are watching these milestones closely, as the FDA's recent acceptance of Coya's drug application and a triggered milestone payment bring new attention to the company’s clinical and financial strategy. See our latest analysis for Coya Therapeutics. After announcing the equity...
ASX:ASM
ASX:ASMMetals and Mining

Australian Strategic Materials (ASX:ASM): Evaluating Valuation Following $55m Raise and Rare Earths Expansion Plans

Australian Strategic Materials (ASX:ASM) just wrapped up a $55 million institutional placement, fueling the Phase 2 expansion of its Korean Metals Plant. This move is expected to double neodymium alloy production and broaden the company’s role in rare earth supply chains. See our latest analysis for Australian Strategic Materials. It has been a wild ride for Australian Strategic Materials’ share price lately. After a huge 92.7% surge in the past month, driven by the capital raise and plans to...
NasdaqCM:FRMM
NasdaqCM:FRMMBiotechs

ETHZilla (ETHZ): Evaluating Valuation After $15 Million Liquidity.io Partnership and Strategic Platform Expansion

ETHZilla is drawing attention after unveiling a $15 million strategic partnership with Satschel, Inc., parent of Liquidity.io. This collaboration gives ETHZilla a 15% equity stake as well as exclusive rights within regulated digital asset markets. See our latest analysis for ETHZilla. Momentum has picked up again for ETHZilla after the Satschel investment, with the share price jumping 17.38% in just the last day and 7.32% over the past week, though recent news-fueled rallies come against the...
NYSE:WEC
NYSE:WECIntegrated Utilities

Is WEC Energy Group Fairly Priced After 23% Climb and Renewable Energy Headlines?

Thinking about whether to buy, sell, or simply hold WEC Energy Group stock? You’re definitely not alone. WEC has been a staple for many portfolios, and its share price reflects that consistency. Over the last year, the stock has climbed 23.3%. For longer-term investors, the gains are even more solid, with a 40.8% increase over the last three years and 35.9% over five years. Even its performance year to date hasn’t gone unnoticed, jumping 23.2%. That said, the past week brought a modest 0.9%...